Loading
Leo International Precision Health Aktiengesellschaft Stock: price and insider trades · Germany
1 insider bought €56k of shares over the last 90 days, the latest filed 31 Jul 2026.
Leo International Precision Health Aktiengesellschaft: what insiders have been doing
Leo International Precision Health Aktiengesellschaft, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to BaFin. Between 18 October 2025 and 18 October 2026, 5 insiders published 11 filings.
On the market, 2 insiders bought (2 purchases totalling €656k) while 1 insider sold (3 sales totalling €216k). The net balance comes to €439k on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 2 board members. Wang, Mr Leo filed the largest purchase, €600k, on 29 May 2026.
The last purchase on record was published on 31 July 2026, which is 78 days ago. Typically, a trade is published a median of 7 days after it takes place. The regulation allows three business days to notify a trade (MAR article 19). Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (287 companies, median 5 filings), a count of 11 filings is above the norm. The full history, which starts in 2025, counts 2 purchases against 3 sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Insider Decl.
11
Thresholds
n/a
Buy Volume
€655,933
2 ops. · all time
Sell Volume
€216,448
3 ops. · all time
Who traded when
BuySaleHerr Leo Wang1 buy3 sales
Leo Wang1 buy
Financial data
as of FY 2024FY ended December 2024 · cache
€0.08
Analyst consensus
Income statement
EBITDA-€149k
Net income-€149k0.0% margin
Balance sheet & cash
Market cap€8.1M
Free Cash Flow-€107k
Profitability & ownership
% insiders84.2%
% institutions0.0%
Last declaration on 16 October 2026
Declarations11 total
141,312 shares@ €1.001.75% mcap51.9% of flowShareISIN DE0005490601BAFIN:40001640-232b501ae147
33,855.422 shares@ €0.830.35% mcap10.3% of flowShareISIN DE0005490601BAFIN:40001640-665808d32fb7
47,036 shares@ €1.000.59% mcap45.7% of flowShareISIN DE0005490601BAFIN:40001640-40897637c198
ShareISIN DE0005490601BAFIN:40001640-e480c1260d52
ShareISIN DE0005490601BAFIN:40001640-8eb1014a09dd
2,500.335 shares@ €22.370.60% mcap100.0% of flowShareFrankfurter WertpapierbörseISIN DE0005490601BAFIN:40001640-a7913a2700bd
Canonical exit: 25 Oct 2026 (T+90)
24,000 shares@ €25.00100.0% of flowShareISIN DE0005490601BAFIN:40001640-cf07a6202f33
Canonical exit: 20 Aug 2026 (T+90)
472,687.5 shares@ €0.3233.5% of flowShareISIN DE0005490601BAFIN:40001640
447,761.194 shares@ €0.6766.5% of flowShareISIN DE0005490601BAFIN:40001640-8cf34c18a78c
11 of 11 declarations
About Leo International Precision Health Aktiengesellschaft
Leo International Precision Health Aktiengesellschaft (ISIN DE0005490601, ticker LEOW.DE) is a German-listed company trading on Xetra/Frankfurt (DAX/MDAX/SDAX), with its market presence effectively on the Frankfurt Stock Exchange’s General Standard segment. The company is incorporated in Germany, with operational headquarters in Planegg/Martinsried near Munich, while corporate registry and governance information also reference Düsseldorf. Formerly known as SPOBAG Aktiengesellschaft, the company was transformed through a reverse takeover into a publicly listed precision-health platform focused on artificial intelligence.
Today, Leo International Precision Health AG operates as an investment and holding company building an integrated AI-driven healthcare ecosystem. Its strategic scope spans biotech, MedTech, HealthTech and healthcare services. Rather than functioning as a single-product drug developer, the group is designed as a platform owner and consolidator: it acquires, holds and develops complementary healthcare assets, then seeks to create value through portfolio integration, operational alignment and cross-asset synergies. According to company disclosures, the investment case is centered on combining technology, data, operations and capital to accelerate the monetization of innovative healthcare assets.
Read moreShow less
From a business-line perspective, the company’s activities are mainly investment-led: ownership of portfolio companies, strategic development, licensing and management of intellectual property, and the build-out of an ecosystem around precision health. The official messaging indicates exposure to AI-enabled healthcare businesses, which may include software, digital health solutions, medical technology, research and development capabilities, and related commercial services. Importantly, the company is still in an early formation stage: its 2025 results state that the consolidated group structure was created only at the end of 2025 and that six portfolio companies were first consolidated during that period, leaving limited historical operating comparability.
In competitive terms, Leo International Precision Health AG aims to position itself as a capitalized consolidation vehicle in a fragmented and fast-evolving precision medicine and healthcare technology market. Its potential advantages include access to the German capital markets, a listed structure, and a strategy built around acquiring and integrating assets rather than relying on a single technology platform. However, the investment profile also carries significant execution risk, including integration complexity, ongoing financing needs, and regulatory exposure across healthcare, data and intellectual-property domains.
Recent highlights are material. In December 2025, the company completed the acquisition of its first six holdings through a capital increase in kind. In April 2026, it published its 2025 annual results, confirming that the group had laid the strategic foundation for its AI-driven precision-health platform and signaling continued portfolio expansion and integration work in 2026. For international investors, LEOW.DE is therefore best understood as an emerging German-listed health-and-AI platform with early-stage operating visibility, a consolidator strategy, and a potentially attractive but still highly developmental risk-return profile.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
